Sales of injectable anti-HIV therapeutics will reach $2 billion in 2029: GlobalData
Cabotegravir-based therapies are projected to generate 79 per cent of the sales of injectable therapeutics in the HIV market in…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
cabotegravir
US FDA approves ViiV Healthcare’s Cabenuva as complete long-acting regimen for HIV treatment
Cabenuva allows virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or…